VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ICML 2021 | Liquid biopsies in monitoring lymphoma

Ash Alizadeh, MD, PhD, Stanford Comprehensive Cancer Center, Stanford, CA, discusses liquid biopsy research for monitoring lymphoma. Liquid biopsies can provide a non-invasive method for genotyping the tumor and monitoring the patient’s condition, especially in patients with aggressive lymphoma. Dr Alizadeh additionally focuses on the potential role liquid biopsies have in terms of clinical translation and minimal residue disease (MRD) testing. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).

Transcript (edited for clarity)

I gave a presentation that focused on historical perspectives on the development of tools and techniques for liquid biopsies as a non-invasive window into a variety of tumors, but with the particular focus on lymphomas and the opportunities for leveraging this pretty powerful tool for specific exercises through the oncology milestones of the typical patient with common lymphomas, focusing on genotyping and monitoring of the disease and shared some of the data from several of the important studies, largely focused on aggressive lymphomas, but with emerging data and other lymphoma types...

I gave a presentation that focused on historical perspectives on the development of tools and techniques for liquid biopsies as a non-invasive window into a variety of tumors, but with the particular focus on lymphomas and the opportunities for leveraging this pretty powerful tool for specific exercises through the oncology milestones of the typical patient with common lymphomas, focusing on genotyping and monitoring of the disease and shared some of the data from several of the important studies, largely focused on aggressive lymphomas, but with emerging data and other lymphoma types.

The presentation was mostly focused on opportunities for how to leverage these ideas for clinical translation of liquid biopsy monitoring and minimal residual disease testing with more glass half-empty than half-full, with the idea of trying to fix the challenges or address the challenges to maximize opportunities for success in the translation.

Read more...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter